4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 101 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $204 | -99.0% | 16 | -98.6% | 0.00% | – |
| Q2 2023 | $20,346 | +5.1% | 1,126 | 0.0% | 0.00% | – |
| Q1 2023 | $19,355 | -44.5% | 1,126 | -28.2% | 0.00% | – |
| Q4 2022 | $34,847 | +190.4% | 1,569 | 0.0% | 0.00% | – |
| Q3 2022 | $12,000 | +9.1% | 1,569 | +111.5% | 0.00% | – |
| Q1 2022 | $11,000 | -99.1% | 742 | -98.7% | 0.00% | -100.0% |
| Q4 2021 | $1,248,000 | -54.9% | 56,939 | -44.6% | 0.00% | -60.0% |
| Q3 2021 | $2,770,000 | – | 102,717 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 1,566,895 | $23,691,000 | 5.12% |
| Aquilo Capital Management, LLC | 1,755,506 | $26,543,000 | 3.90% |
| Deep Track Capital, LP | 2,448,200 | $37,017,000 | 2.37% |
| BVF INC/IL | 2,664,521 | $40,288,000 | 1.61% |
| Opaleye Management Inc. | 325,000 | $4,914,000 | 1.53% |
| Perigon Wealth Management, LLC | 557,475 | $8,429,000 | 0.60% |
| Eagle Health Investments LP | 132,090 | $1,997,000 | 0.49% |
| Casdin Capital, LLC | 555,455 | $8,398,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $59,541,000 | 0.24% |
| ArrowMark Colorado Holdings LLC | 1,145,585 | $17,321,000 | 0.15% |